AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01051609 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound of Hand/Wrist
Description: An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
Study NCT03738839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect bonding
Description: For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
Study NCT03738839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect bonding
Description: For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
Study NCT02348684 — intervention group
Intervention type: RADIATION
Intervention: Radiation therapy groups
Description: Radiation Therapy treatment between 2000 and 2007.
Study NCT02307201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: The patient will receive magnesium sulfate for 24 hours postpartum
Study NCT04338854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restorative Treatment
Description: 9 groups were formed as 6 restorative and 3 protective applications. The restorative treatment groups included procedures with- and without-local anesthesia (LA). Procedures with LA included the groups as root canal treatment, pulpotomy, two-surface restoration and one-surface restoration. Procedures without LA included the groups as two-surface restoration and one-surface restoration. The protective application groups included the groups as fluoride application (by disposable arch tray or by cotton roll) and fissure sealant.
Study NCT00977756 — intervention group
Intervention type: DRUG
Intervention: Raltegravir (RAL)
Description: 400 mg twice daily (BID)
Study NCT00977756 — intervention group
Intervention type: DRUG
Intervention: Atazanavir (ATV)
Description: 300 mg daily
Study NCT01095003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine plus Capecitabine
Description: Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
Study NCT01095003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
Study NCT04122222 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.
Study NCT02771665 — intervention group
Intervention type: OTHER
Intervention: Mammographic breast density at diagnosis
Description: Mammographic breast density at diagnosis
Study NCT01191021 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol Anesthesia
Description: Volunteers will undergo propofol anesthesia for 90 min.
Study NCT01241942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steen Solution™
Description: This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNC Hospitals (UNCH) where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNCH based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.
Study NCT01241942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Lung Transplant
Description: No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
Study NCT03468036 — intervention group
Intervention type: OTHER
Intervention: none, does not apply
Description: none: does not apply
Study NCT03152461 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT01696591 — intervention group
Intervention type: BIOLOGICAL
Intervention: NEUROSTEM®-AD
Description: NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
Study NCT04292106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Spinach Extract (RSE)
Description: Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 7 days
Study NCT04292106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules will be taken consisting of maltodrextrin daily for 7 days
Study NCT04104958 — intervention group
Intervention type: GENETIC
Intervention: qRTPCR (mRNA level).
Description: RNA extraction and RT-qPCR Protein extraction and western blotting ELISA assay
Study NCT01838902 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DHA-PPQ
Description: Participants will receive a 3 day course of DHA-PPQ
Study NCT01838902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-PPQ
Description: Participants will receive a 3 day course of DHA-PPQ
Study NCT01838902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ (0.75)
Description: Participants will receive a single dose of PQ at 0.75mg base/kg body weight
Study NCT01838902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ (0.4)
Description: Participants will receive a single dose of PQ at 0.4mg base/kg body weight
Study NCT01838902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ (0.2)
Description: Participants will receive a single dose of PQ at 0.2mg base/kg body weight
Study NCT00766584 — intervention group
Intervention type: OTHER
Intervention: Sleep apnea/hypopnea detection
Description: Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
Study NCT02224391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Smoking Cessation Intervention
Description: Receive ABM training via a smartphone
Study NCT02224391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02224391 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02224391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Given via transdermal patch
Study NCT02224391 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Nicotine Patch
Description: Given via transdermal patch
Study NCT02224391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02224391 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02224391 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham training
Study NCT00977756 — intervention group
Intervention type: DRUG
Intervention: Ritonavir (RTV)
Description: 100 mg daily, dosing by weight in Group I
Study NCT00977756 — intervention group
Intervention type: DRUG
Intervention: Tenofovir (TDF)
Description: 300 mg daily
Study NCT00977756 — intervention group
Intervention type: DRUG
Intervention: Etravirine (ETV)
Description: 200 mg BID
Study NCT00977756 — intervention group
Intervention type: DRUG
Intervention: Darunavir (DRV)
Description: Dosing by weight
Study NCT00977756 — intervention group
Intervention type: DRUG
Intervention: Maraviroc (MVC)
Description: 150 mg BID in groups J and K; 600 mg BID in group L
Study NCT00977756 — intervention group
Intervention type: DRUG
Intervention: Lopinavir/ritonavir (LPV/r)
Description: Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
Study NCT01715974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF group
Description: 30 micrograms/day of GM-CSF from the day of embryo transfer through the day of beta HCG test
Study NCT01715974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: saline infusion every day from the day of embryo transfer through the day of beta HCG test
Study NCT02857426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT03587142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: Buspirone tablet
Study NCT03587142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic buspirone 10 mg tablet
Study NCT00677443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 & Oxaliplatin
Description: S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
Study NCT00677443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine & Oxaliplatin
Description: COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
Study NCT04772846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral tablet
Description: Oral 250mg chloroquine tablets
Study NCT03847753 — intervention group
Intervention type: OTHER
Intervention: Substance Use Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study NCT03847753 — intervention group
Intervention type: OTHER
Intervention: Schizophrenia Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study NCT03847753 — intervention group
Intervention type: OTHER
Intervention: Mood disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study NCT03847753 — intervention group
Intervention type: OTHER
Intervention: Neurotic disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study NCT03847753 — intervention group
Intervention type: OTHER
Intervention: Eating Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study NCT03847753 — intervention group
Intervention type: OTHER
Intervention: Personality Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study NCT03847753 — intervention group
Intervention type: OTHER
Intervention: Intellectual Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study NCT03847753 — intervention group
Intervention type: OTHER
Intervention: Developmental Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study NCT03847753 — intervention group
Intervention type: OTHER
Intervention: Behavioral Disorders
Description: Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
Study NCT03025139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Attend survivorship education
Study NCT03025139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03025139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meditation Therapy
Description: Attend mindfulness meditation
Study NCT03025139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04772846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets
Study NCT05908123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Blank Center CARE Model(TM) for Individuals who Stutter
Description: The over-arching goal of the Blank Center CARE Model is to ensure individuals who stutter communicate effectively, advocate for themselves in a manner that maintains agency, and ensure their quality of life does not depend on producing, or attempting to control, stuttered speech.
Study NCT04697641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500 mg twice a day for two weeks
Study NCT04697641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 MG
Description: Amoxicillin 1000mg twice a day for two weeks
Study NCT04697641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40mg
Description: Pantoprazole 40 mg or equivalent for eight weeks
Study NCT04697641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: Pantoprazole 40 mg or equivalent for eight weeks
Study NCT04697641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosulpiride
Description: Levosulpiride 25 mg as and when required before meals
Study NCT04697641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acotiamide
Description: Acotiamide 100mg as when required before meals
Study NCT04697641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride
Description: Itopride 50mg as when required before meals
Study NCT04570865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
Study NCT04570865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS
Description: The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
Study NCT04793529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol injection
Study NCT02751450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride dentifice
Description: Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
Study NCT02751450 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sodium Monofluorophosphate dentifrice
Description: Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
Study NCT02640950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroStar TMS
Description: Transcranial Magnetic Stimulation
Study NCT03734328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: * anesthesia of the palatal mucosa~* subepithelial connective tissue graft harvesting~* suturing (5/0 silk suture)
Study NCT03734328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue graft
Description: * anesthesia of the palatal mucosa~* subepithelial connective tissue graft harvesting~* suturing (5/0 silk suture)
Study NCT00263328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard of care
Study NCT03734328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft&PRF
Description: anesthesia of the palatal mucosa subepithelial connective tissue graft harvesting~-suturing (5/0 silk suture)
Study NCT03734328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: connective tissue graft&PRF
Description: anesthesia of the palatal mucosa subepithelial connective tissue graft harvesting~-suturing (5/0 silk suture)
Study NCT03734328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft&PRF
Description: * taking blood from patient~* centrifuging blood~* obtain PRF
Study NCT03734328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: connective tissue graft&PRF
Description: * taking blood from patient~* centrifuging blood~* obtain PRF
Study NCT03582982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric overload exercise
Description: 12 weeks of 2x per week of the following eccentric exercises: squat, shoulder press, row, and bicep curl.
Study NCT03770962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two midwives
Description: Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will assist her.
Study NCT00263328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 5 mg BID
Study NCT00263328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 10 mg BID
Study NCT03014297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus
Study NCT03014297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosbretabulin
Description: fosbretabulin
Study NCT01404754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose (inactive placebo)
Description: Placebo in an equivalent weight to midomafetamine HCl will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.
Study NCT01404754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midomafetamine HCl
Description: 120 mg midomafetamine HCl will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 40 mg may be administered 1.5 to 2.5 hours later.
Study NCT02698657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP5094
Description: Intravenous (IV)
Study NCT02698657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV)
Study NCT01609543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
Study NCT00467727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase Contrast Mammography
Description: Standard and magnification views
Study NCT04426864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Aerobic Plus Stretching Exercises
Description: An exercise prescription was developed for each woman based on the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70 % ergospirometric VO2max (moderate-intensity) was determined by the submaximal treadmill test. The participants were instructed to perform their exercises at 50 % of VO2max for six weeks. At seventh their exercise intensity was increased to target HR corresponding to 70 % of VO2max. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY). Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. The muscle groups which were involved in stretching exercises were upper trapezius, rhomboid, hip flexor, hamstring, pectoral, piriformis, quadriceps, gastrocnemius, soleus, levator scapulae, hip adductor and tensor fasciae late muscles. The exercise program was applied 3 days a week for 12 weeks.
Study NCT04426864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Resistance Plus Stretching Exercises Group
Description: According to the data obtained from 1-RM tests, an exercise prescription was developed for each woman. The participants were instructed to perform their exercises with 50% of 1-RM for six weeks. In the 7. week, weights were increased to 70-80% of 1-RM. The number of sets increased progressively (10 repetitions per set; 1 set in the first two weeks; 2 sets in the 3rd and 4th week; 3 sets in the 5th and 6th week). The muscle groups which were involved in resistance exercises were bilateral biceps, deltoid, trapezius, pectorals, serratus anterior, latissimus dorsi, levator scapulae, rhomboid, gluteal, quadriceps, hip adductor and abductor, hamstring, gastrocnemius and abdominal muscles. Stretching exercises were performed at the beginning and end of each exercise session. Each muscle group exercise was performed 3-4 times and each repeat was 30 seconds long. Stretching exercises were given for the muscle groups they worked on. The exercise program was applied 3 days a week for 12 weeks.